The Science Behind PQQ for Skin Improvement: Clinical Evidence and Practical Guidance

Pyrroloquinoline quinone (PQQ) is emerging as a potent antioxidant with proven efficacy in skin health improvement, particularly for individuals experiencing photodamage and signs of aging. Groundbreaking research, including a recent clinical trial, has revealed the ultimate benefits of PQQ when used in combination with advanced skincare formulations like retinoids and alpha-hydroxy acids (AHA).

Clinical Trial Highlights: PQQ for Photodamaged Skin

A 12-week, open-label clinical trial was conducted to evaluate the efficacy of PQQ combined with an AHA-retinoid cream in participants with Fitzpatrick skin types IV-V, characterized by higher melanin levels and susceptibility to hyperpigmentation. A total of 21 female participants aged 40-65, with mild to moderate photodamage, were enrolled. The participants applied the regimen twice daily (morning and evening), including a broad-spectrum sunscreen (SPF 56) during the day.

The trial’s primary outcomes were the improvement in skin dullness, texture, tone, and the reduction of fine lines, wrinkles, and erythema (redness). These were assessed using a standardized 10-point grading scale, supplemented by non-invasive instruments like Mexameter to objectively measure melanin and erythema levels.

Key Results and Measurable Improvements

​

Unretouched clinical photography shown on clean, product-free skin using standardized digital imaging. Image descriptions are based on average global improvement scores as assessed by the investigator. Visible improvements demonstrated from baseline following use of the skincare regimen after (A) 4 weeks, average result; (B) 8 weeks, average result; (C) 12 weeks, average result; and (D) 12 weeks, average result.

​

By Week 12, participants exhibited significant improvements across several skin health indicators:

• Skin dullness reduced by 64% (p < 0.0001).

• Skin texture improved by 54% (p < 0.0001).

• Skin tone (discoloration) reduced by 27% (p < 0.0001).

• Fine lines and wrinkles showed a 10% improvement (p < 0.01).

• Erythema decreased significantly by 47% (p = 0.004), contributing to smoother, more even-toned skin.

​

Significant mean reductions from baseline occurred as early as 4 weeks in Mexameter measurements for both erythema and melanin and over the 12-week study period (p< 0.05).

​

Objective melanin and erythema measurements confirmed these findings, demonstrating the antioxidative power of PQQ in reducing oxidative stress and promoting cellular repair.

Dosage and Application Protocol

In this study, PQQ was administered topically, combined with WEL antioxidant technology and an AHA-retinoid formula. The regimen included:

• Twice-daily application of the cream (morning and evening).

• Broad-spectrum sunscreen (SPF 56) applied in the morning to protect against UV damage, particularly essential for photodamaged skin.

Participants followed this routine for 12 weeks, with assessment points at Weeks 4, 8, and 12. Notably, 95% of the participants expressed satisfaction with their skin's improved appearance and indicated they would continue the treatment after the study's conclusion.

Conclusion: Real-World Impact of PQQ on Skin Health

This clinical trial provides robust evidence of PQQ’s ability to improve both extrinsic and intrinsic signs of aging in individuals with darker skin tones. The combination of PQQ with a retinoid and AHA-based skincare regimen resulted in significant enhancements in skin brightness, texture, tone, and reduction in visible aging signs.

For individuals seeking scientifically validated skincare solutions, PQQ offers a powerful, evidence-based option for rejuvenating the skin and combating oxidative stress. With clear improvements in just 12 weeks, PQQ stands out as an essential ingredient in modern dermatological treatments, especially for those looking to enhance skin resilience against environmental and intrinsic aging factors.